What is petrelintide in simple terms?

Petrelintide is an investigational once-weekly injection that mimics amylin, a hormone that promotes fullness. Zealand Pharma developed it and Roche partnered to co-develop it for chronic weight management. It is still in clinical trials.

Why is the Roche partnership notable?

In 2025, Roche agreed to co-develop and co-commercialize petrelintide with Zealand Pharma in a deal worth roughly $1.65 billion upfront plus several billion more in potential milestones, making it one of the largest single-asset obesity collaborations to date.

What did the ZUPREME-1 trial report?

ZUPREME-1, a Phase 2b trial in people with overweight or obesity without type 2 diabetes, reported up to about 10.7% mean body-weight reduction at 42 weeks versus about 1.7% for placebo, with a tolerability profile the partners highlighted. These are trial findings, not an approval.

How is petrelintide different from cagrilintide or eloralintide?

All three target amylin. Petrelintide (Zealand/Roche) and eloralintide (Lilly) are advanced selective amylin agents. Cagrilintide (Novo Nordisk) is the amylin half of the combination CagriSema. Petrelintide is also being studied in combination with an incretin drug.

Medical Supervision Required: Peptide Tracker is for private logging, calculations, reminders, inventory records, and education. It is not medical advice, dosing instruction, prescribing guidance, diagnosis, or a substitute for a qualified healthcare professional.

Compound Names

What Is Petrelintide?

Published Jun 22, 2026 · 5 minute read

Petrelintide is an investigational long-acting amylin analog from Zealand Pharma, partnered with Roche. Like other amylin drugs, it works through the satiety hormone amylin rather than the GLP-1 pathway, and it drew attention partly because of the size of the Roche deal behind it. It is still in clinical trials.

Key Takeaways

Petrelintide (code name ZP8396) is a long-acting amylin analog developed by Zealand Pharma.
It is partnered with Roche in one of the largest single-asset obesity deals to date.
It works through the amylin pathway, distinct from the GLP-1 and GIP incretin pathways.
It is not FDA-approved as of June 2026 and is available only to clinical-trial participants.
Phase 2b (ZUPREME-1) read out in March 2026; the partners committed to advance to Phase 3 in the second half of 2026.
Trial results describe population-level research findings, not personal medical expectations.

1. What Is Petrelintide?

Petrelintide is an investigational molecule developed by Zealand Pharma, a Danish biotech. Its development code name is ZP8396. It is a long-acting amylin analog designed for once-weekly subcutaneous dosing.

Petrelintide belongs to the amylin family rather than the incretin (GLP-1/GIP) family. It sits alongside eloralintide and cagrilintide as one of the most advanced amylin-based weight-management candidates.

Term	What it means
Petrelintide	Zealand Pharma’s investigational amylin analog.
ZP8396	The development code name for petrelintide.
Amylin	A hormone co-released with insulin that promotes fullness.
ZUPREME	Zealand and Roche’s Phase 2b clinical program.

2. How Does Petrelintide Work?

Amylin is a hormone secreted alongside insulin. Activating amylin receptors induces satiety directly, and amylin signaling has also been linked to restoring sensitivity to leptin, another hormone involved in appetite regulation. This is a distinct mechanism from the GLP-1 and GIP incretin pathways used by semaglutide and tirzepatide.

Because the pathway is different and complementary, petrelintide is being developed both as a standalone therapy and as a foundation for amylin-plus-incretin combinations.

3. The Roche Partnership

In March 2025, Roche agreed to co-develop and co-commercialize petrelintide with Zealand Pharma. The deal included roughly $1.65 billion upfront plus up to several billion dollars more in potential development and sales milestones, with the partners sharing profits in major markets. It stands as one of the largest single-asset obesity collaborations to date, which is part of why petrelintide draws outsized attention relative to its trial stage.

4. Is Petrelintide FDA-Approved?

No. Petrelintide is not FDA-approved as of June 2026. It is investigational, has no marketed product, and is available only through clinical trials run by Zealand Pharma and Roche. As of mid-2026, the partners had reported positive Phase 2b data and committed to advancing to Phase 3.

5. What Did the ZUPREME Trials Show?

ZUPREME-1 (NCT06662539) was a Phase 2b, randomized, double-blind, placebo-controlled, dose-finding trial of roughly 493 adults with overweight or obesity, without type 2 diabetes, dosed once weekly for 42 weeks. In March 2026, the partners reported up to about 10.7% mean body-weight reduction at week 42 versus about 1.7% for placebo, and highlighted the tolerability profile at the most effective dose.

Fact	Details
Trial	ZUPREME-1, NCT06662539 (Phase 2b).
Population	~493 adults with overweight or obesity, without type 2 diabetes.
Time frame	42 weeks.
Reported result	Up to ~10.7% weight loss vs ~1.7% placebo.

A second Phase 2b trial, ZUPREME-2 (NCT06926842), is studying petrelintide in people who also have type 2 diabetes, with topline results expected in the second half of 2026. These figures are trial-population averages, not personal predictions.

6. Petrelintide and the Amylin Field

Petrelintide is one of several amylin candidates racing through development:

Selective / standalone amylin agents: petrelintide (Zealand/Roche) and eloralintide (Lilly).
Amylin analog in a combination: cagrilintide (Novo Nordisk), the amylin half of CagriSema.
Single-molecule GLP-1/amylin agonist: amycretin (Novo Nordisk).

Petrelintide is also notable for its planned combination program, pairing it with an incretin (GLP-1/GIP) partner molecule to test amylin-plus-incretin therapy.

7. Where Petrelintide Stands

Petrelintide is the molecule; ZP8396 is its code name.
Investigational describes its regulatory status.
Long-acting amylin analog is the accurate mechanism description.
Amylin, not GLP-1, is the pathway it works through.

8. What Is Petrelintide FAQ

What is petrelintide in simple terms?

Petrelintide is an investigational once-weekly injection that mimics amylin, a hormone that promotes fullness. Zealand Pharma developed it and Roche partnered to co-develop it for chronic weight management. It is still in clinical trials.
Is petrelintide FDA-approved?

No. Petrelintide is investigational and not approved by the FDA or any regulator as of June 2026. It is available only to participants in clinical trials run by Zealand Pharma and Roche.
Why is the Roche partnership notable?

In 2025, Roche agreed to co-develop and co-commercialize petrelintide with Zealand Pharma in a deal worth roughly $1.65 billion upfront plus several billion more in potential milestones, making it one of the largest single-asset obesity collaborations to date.
What did the ZUPREME-1 trial report?

ZUPREME-1, a Phase 2b trial in people with overweight or obesity without type 2 diabetes, reported up to about 10.7% mean body-weight reduction at 42 weeks versus about 1.7% for placebo, with a tolerability profile the partners highlighted. These are trial findings, not an approval.
How is petrelintide different from cagrilintide or eloralintide?

All three target amylin. Petrelintide (Zealand/Roche) and eloralintide (Lilly) are advanced selective amylin agents. Cagrilintide (Novo Nordisk) is the amylin half of the combination CagriSema. Petrelintide is also being studied in combination with an incretin drug.

9. Sources

References used for this article